BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27443782)

  • 1. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
    Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
    Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
    Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
    Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study.
    Lemoine M; Shimakawa Y; Njie R; Taal M; Ndow G; Chemin I; Ghosh S; Njai HF; Jeng A; Sow A; Toure-Kane C; Mboup S; Suso P; Tamba S; Jatta A; Sarr L; Kambi A; Stanger W; Nayagam S; Howell J; Mpabanzi L; Nyan O; Corrah T; Whittle H; Taylor-Robinson SD; D'Alessandro U; Mendy M; Thursz MR;
    Lancet Glob Health; 2016 Aug; 4(8):e559-67. PubMed ID: 27443781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
    Mokaya J; Burn EAO; Tamandjou CR; Goedhals D; Barnes EJ; Andersson M; Pinedo-Villanueva R; Matthews PC
    BMC Public Health; 2019 Jun; 19(1):829. PubMed ID: 31242901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study.
    Nayagam S; de Villiers MJ; Shimakawa Y; Lemoine M; Thursz MR; Walsh N; Hallett TB
    Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):635-645. PubMed ID: 37150181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia.
    Schmit N; Nayagam S; Lemoine M; Ndow G; Shimakawa Y; Thursz MR; Hallett TB
    J Glob Health; 2023 Jan; 13():04004. PubMed ID: 36655869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
    Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load.
    Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
    Obstet Gynecol; 2014 May; 123(5):929-937. PubMed ID: 24785842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
    Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
    Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
    Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
    Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.
    Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N
    BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model.
    Jing W; Liu J; Wu Y; Ma Q; Liu M
    EClinicalMedicine; 2020 Feb; 19():100264. PubMed ID: 32055793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.
    Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
    Hepatology; 2016 May; 63(5):1471-80. PubMed ID: 26509655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.